Antiprogestins inhibit growth and stimulate differentiation in the normal mammary gland.
Antiprogestins possess a potent antitumor activity in hormone-dependent experimental breast cancer models. Though the underlying mechanism is not clear, induction of functional differentiation seems to be a major event. This study attempts to test directly for antiproliferative and differentiation promoting activities of antiprogestins on the normal mammary gland. To this end, whole organ cultures of mammary glands from estradiol/progesterone-primed virgin mice maintained in a serum-free medium with aldosteron, prolactin, insulin, and hydrocortisone were exposed to the antiprogestin ZK114043. A 4-day treatment of organ cultures led to a strong inhibition of epithelial DNA synthesis. In parallel, ZK114043 caused alveolar cells to acquire a more differentiated phenotype distinguished by secretory active alveoli composed of single cell layers with increased fat droplet accumulation and enhanced expression of the milk proteins beta-casein and whey acidic protein (WAP). Particularly strong effects were found on the expression of mammary-derived growth inhibitor (MDGI). Both half-maximal inhibition of epithelial DNA synthesis and stimulation of MDGI mRNA expression were found at about 5 ng/ml of ZK114043. Presence in the medium of 5 micrograms/ml hydrocortisone rendered antiglucocorticoid effects of ZK114043 highly unlikely. Furthermore, prevention of action of ZK114043 by the progesterone agonist R5020 and ZK114043 stimulated expression of beta-casein and MDGI mRNA in cultured glands of 10-week-old unprimed virgin mice suggest a progesterone receptor-mediated mechanism of antiprogestin action. Two other antiprogestins, Mifepristone and Onapristone, likewise stimulated MDGI expression. The data provide direct evidence that antiprogestins act like a differentiation factor in the normal mammary gland.
Li
M
M
VA Medical Center Research Services, Baltimore, Maryland 21201, USA.
Spitzer
E
E
Zschiesche
W
W
Binas
B
B
Parczyk
K
K
Grosse
R
R
D000818:Animals; D002352:Carrier Proteins; D002364:Caseins / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects; D004247:DNA / Q000037:antagonists & inhibitors; D004847:Epithelial Cells; D004848:Epithelium / Q000187:drug effects; D000074026:Fatty Acid Binding Protein 3; D050556:Fatty Acid-Binding Proteins; D005260:Female; D006131:Growth Inhibitors / Q000494:pharmacology*; D008321:Mammary Glands, Animal / Q000166:cytology / Q000187:drug effects*; D051379:Mice; D008807:Mice, Inbred BALB C; D015735:Mifepristone / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D008894:Milk Proteins / Q000378:metabolism; D009924:Organ Culture Techniques; D010455:Peptides / Q000378:metabolism; D010641:Phenotype; D011372:Progestins / Q000037:antagonists & inhibitors*
D002352:Carrier Proteins; D002364:Caseins; C493409:Fabp3 protein, mouse; D000074026:Fatty Acid Binding Protein 3; D050556:Fatty Acid-Binding Proteins; D006131:Growth Inhibitors; D008894:Milk Proteins; D010455:Peptides; D011372:Progestins; C024471:whey acidic proteins; C094270:ZK 114043; D015735:Mifepristone; D004247:DNA